A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
Spotlight on prescriber-pharmacist relationships
Leaders from pharmacy, medical and consumer organisations will gather in Canberra on Tuesday to explore how doctors and pharmacists can better cooperate to support...
Out of the shadows
Pharmacists are embracing new opportunities to play a greater role in multidisciplinary teams focused on mental health.
Australian Pharmacist spoke with two mental health...
Alzheimer’s saliva test a potential breakthrough, but caution needed
More research has been urged after the creator of a breakthrough test for detecting Alzheimer’s disease said the test could be combined with daily...
Cost savings from pharmacist-led post-discharge care
US research has found pharmacist-led post-discharge care for high-risk patients resulted in fewer admissions and healthcare cost savings of more than $US500 per patient.
In...
Aged care antimicrobial prescribing on the rise
Data released last month shows an increase in the number of aged care residents prescribed antimicrobials, highlighting the need for pharmacists to use their...
Inquiry reveals the depth of Australia’s sleep deficit problem
The recently released government inquiry into sleep health identified the extent of the nation's sleep deficit and its impact on health, risk of accidents...
